Xeris Pharmaceuticals Inc (XERS)
Healthcare
Drug Manufacturers - Specialty & Generic
8.10 $
-4.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Xeris Pharmaceuticals Inc (XERS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.5% of the shares are freely tradable; institutional investors hold 62.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
62.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
96.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
6.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
173Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 7.50 | 12,945,785 | +2.4 | 03/31/2026 |
| D. E. Shaw & Co LP | 4.51 | 7,788,811 | +2.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.04 | 6,980,882 | +0.0 | 03/31/2026 |
| State Street Corp | 2.70 | 4,658,174 | +13.1 | 03/31/2026 |
| Geode Capital Management, LLC | 2.49 | 4,290,629 | +0.3 | 03/31/2026 |
| Qube Research & Technologies | 2.38 | 4,114,425 | +17.6 | 03/31/2026 |
| Rosalind Advisors, Inc. | 1.87 | 3,231,700 | +53.0 | 03/31/2026 |
| Nuveen, LLC | 1.69 | 2,916,598 | +3.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 3.01 | 5,193,656 | +4.9 | 06/30/2026 |
| iShares Russell 2000 ETF | 2.57 | 4,436,113 | -0.1 | 07/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.